Impact of socioeconomic status on cancer staging, survival in non-small cell lung cancer

Yang, Xianghui; Deng, Liyong; Li, Min; Zhou, Yongjie; Wang, Guihua

doi:10.3389/fpubh.2022.992944

Cited by 4 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, icariin activated the mitochondrial signaling pathway and induced apoptosis of A540 lung cancer cells by inhibiting the phosphorylation of AKT (Wu et al, 2019). In a similar vein, it has been shown that icariin promotes the inhibition of lung cancer cell proliferation and migration by activating the CaMKII/JNK signaling pathway (Yang et al, 2020) and the endoplasmic reticulum stress signaling (Di et al, 2015;Wen et al, 2020;Rawal et al, 2023). Icariin also acts against bone metastasis in nude mice with lung cancer by inhibiting the receptor activator of nuclear factor kappa-B-ligand (RANKL) while increasing osteoprotegerin (OPG) expression (Ruilian et al, 2022).…”

Section: Lung Cancermentioning

confidence: 81%

Icariin as a potential anticancer agent: a review of its biological effects on various cancers

et al. 2023

View full text Add to dashboard Cite

Numerous chemical compounds used in cancer treatment have been isolated from natural herbs to address the ever-increasing cancer incidence worldwide. Therein is icariin, which has been extensively studied for its therapeutic potential due to its anti-inflammatory, antioxidant, antidepressant, and aphrodisiac properties. However, there is a lack of comprehensive and detailed review of studies on icariin in cancer treatment. Given this, this study reviews and examines the relevant literature on the chemopreventive and therapeutic potentials of icariin in cancer treatment and describes its mechanism of action. The review shows that icariin has the property of inhibiting cancer progression and reversing drug resistance. Therefore, icariin may be a valuable potential agent for the prevention and treatment of various cancers due to its natural origin, safety, and low cost compared to conventional anticancer drugs, while further research on this natural agent is needed.

show abstract

Section: Lung Cancermentioning

confidence: 81%

Icariin as a potential anticancer agent: a review of its biological effects on various cancers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Socio-economic status, both at the individual level and area level, has been associated with survival in lung cancer patients ( 38 , 39 ). In our study, area-level socio-economic status was not associated with mortality.…”

Section: Discussionmentioning

confidence: 99%

Survival of bronchopulmonary cancers according to radon exposure

Dessemon,

Perol,

Chauvel

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

IntroductionResidential exposure is estimated to be responsible for nearly 10% of lung cancers in 2015 in France, making it the second leading cause, after tobacco. The Auvergne-Rhône-Alpes region, in the southwest of France, is particularly affected by this exposure as 30% of the population lives in areas with medium or high radon potential. This study aimed to investigate the impact of radon exposure on the survival of lung cancer patients.MethodsIn this single-center study, patients with a histologically confirmed diagnosis of lung cancer, and newly managed, were prospectively included between 2014 and 2020. Univariate and multivariate survival analyses were carried out using a non-proportional risk survival model to consider variations in risk over time.ResultsA total of 1,477 patients were included in the analysis. In the multivariate analysis and after adjustment for covariates, radon exposure was not statistically associated with survival of bronchopulmonary cancers (HR = 0.82 [0.54–1.23], HR = 0.92 [0.72–1.18], HR = 0.95 [0.76–1.19] at 1, 3, and 5 years, respectively, for patients residing in category 2 municipalities; HR = 0.87 [0.66–1.16], HR = 0.92 [0.76–1.10], and HR = 0.89 [0.75–1.06] at 1, 3, and 5 years, respectively, for patients residing in category 3 municipalities).DiscussionAlthough radon exposure is known to increase the risk of lung cancer, in the present study, no significant association was found between radon exposure and survival of bronchopulmonary cancers.

show abstract

“…The increased prevalence of MPE within our cohort may also be reflective of high levels of socioeconomic deprivation in the North East of England, with 54.6% of households classified as deprived in the latest Census report (the highest proportion in England) [ 15 ]. Poor socioeconomic status has been linked to more advanced stage disease at presentation in patients with non-small cell lung cancer, as this group of patients is more likely to experience barriers to presentation [ 16 , 17 ]. Delayed presentation could therefore account for a higher proportion of patients presenting with effusions.…”

Section: Discussionmentioning

confidence: 99%

Small Cell Lung Cancer and Pleural Effusion: An Analysis from a District General Hospital

Keidan

Aujayeb

2023

Pulm Ther

View full text Add to dashboard Cite

Introduction The incidence of malignant pleural effusion (MPE) in patients with small cell lung cancer (SCLC) in an American population is approximately 11%, and overall survival in that group is 3 months (compared to 7 months without an effusion. To our knowledge, no study has been done in the United Kindgom and we thus sought to determine the characteristics of the local population. Method All patients coded as having small cell lung cancer from Somerset register from January 2012–September 2021 were reviewed. We excluded those with indeterminate pathology reports, carcinoid or large cell neuroendocrine cancers. Basic demographics, presence of an MPE and any interventions and outcomes were collected for descriptive analysis. Continuous variables are presented as mean (±) range, median (± IQR) when outliers were present and categorical variables as percentages where appropriate. Caldicott reference C3905. Results Four hundred one patients with SCLC were identified (11% of all patients, median time to death from presentation 208 days, IQR 304 [many outliers); 224 (55.9%) were female, 177 male [median age 75 years, IQR 13]. One hundred seven (27%) presented with an effusion: 23 were sampled, 10 had positive cytology, all were exudates, 8 required chest drainage, the mean performance status (PS) was 2 (range 1–4) and the median time to death 142 days, IQR 45. Of the 294 with no initial effusions, 70 (24%) developed a pleural effusion with progressive disease (mean PS 1, median age 71.5 years, IQR 14, median to death 327 days, IQR 395, 1 outlier); 224 patients never had a MPE with a median time to death of 212 days, IQR 305, multiple outliers and, when compared to those with a MPE at any point, median time to death was 211 days, IQR 295.5 (multiple outliers). Conclusion Meaningful analysis was difficult because of the presence of multiple outliers in values collected and not correcting for stage at presentation or treatment modalities and previous studies did not correct for those either. Those presenting with an MPE had a poorer prognosis, probably signifying advanced disease and the presence of MPE in our SCLC cohort seems higher. Large prospective databases for this are required.

show abstract

Impact of socioeconomic status on cancer staging, survival in non-small cell lung cancer

Cited by 4 publications

References 42 publications

Icariin as a potential anticancer agent: a review of its biological effects on various cancers

Icariin as a potential anticancer agent: a review of its biological effects on various cancers

Survival of bronchopulmonary cancers according to radon exposure

Small Cell Lung Cancer and Pleural Effusion: An Analysis from a District General Hospital

Contact Info

Product

Resources

About